Points clés
- 1Generics are chemically identical small-molecule copies; biosimilars are highly similar versions of complex proteins that cannot be made identical.
- 2Biosimilar approval rests on a comparability programme — analytical, non-clinical and clinical — not a single bioequivalence study.
- 3Biosimilars typically bring moderate-to-large price reductions; they are not automatically substituted at the pharmacy in most systems.
- 4Record the product and batch at each administration — biologic pharmacovigilance is product-specific.
Sur cette page
1The core difference is molecular size and complexity
A small-molecule drug such as atorvastatin is a defined chemical structure that can be synthesised to be identical every time. A generic is therefore chemically the same molecule.
A biologic such as trastuzumab or adalimumab is a large protein produced by living cells. Even the originator's own batches vary slightly within accepted limits, because biological systems are not chemical reactors. An exact copy is not scientifically achievable.
Hence 'biosimilar' — highly similar, with no clinically meaningful differences — rather than 'generic'.
| Aspect | Generic | Biosimilar |
|---|---|---|
| Source molecule | Chemically synthesised | Produced by living cells |
| Molecular size | Small, well defined | Large, complex |
| Copy standard | Identical active ingredient | Highly similar, no clinical difference |
| Core evidence | Bioequivalence study | Comparability programme incl. clinical data |
| Typical price reduction | Very large | Moderate to large |
| Substitution at pharmacy | Often automatic | Often requires prescriber decision |
2How biosimilars are approved
Approval rests on a comparability exercise rather than a single study: extensive analytical characterisation of structure and function, non-clinical work, pharmacokinetic comparison, and clinical data in a sensitive indication where a difference would be detectable.
Regulators may then permit extrapolation to other indications of the reference product where the mechanism of action justifies it. Post-marketing safety monitoring, including immunogenicity surveillance, continues after approval.
3What this means for your treatment
If you are offered a biosimilar, it is reasonable to accept it when your specialist recommends it — this is now standard practice across many oncology, rheumatology and gastroenterology services.
Practical points worth raising: record the specific product name and batch number at each administration, since biologic pharmacovigilance is product-specific; ask whether the delivery device differs, as device technique matters; and agree what will be monitored after the switch.
- Note the exact brand and batch at every dose.
- Ask whether the injection device or administration method changes.
- Agree monitoring parameters and a review date.
- Report any new injection-site or systemic reaction promptly.
Ce que montre le jeu de données Jivan
- 59×
- écart moyen de prix
- 84%
- des ancres dépassent 10×
- 344×
- plus grand écart documenté
Across our full referenced dataset, 476 referenced molecules average a 59× price gap, 84% of them are at least 10× cheaper in India, and the widest documented comparison is Colchicine at 344×. Across the full referenced dataset the gap is systematic rather than anecdotal: 84% of anchored molecules are at least 10× cheaper, with a 59× average ratio — a market-structure effect repeated across all 26 therapy areas.
Calculé en direct à partir de 476 anchors
Questions fréquentes
No. A generic contains an identical small molecule. A biosimilar is a highly similar version of a complex biologic, approved through a comparability pathway rather than a simple bioequivalence study.
Rules vary by country. In many systems biosimilar switching is a prescriber decision rather than an automatic pharmacy substitution, though some jurisdictions permit interchangeable designation.
Development requires extensive analytical and clinical comparability work plus specialised biological manufacturing, so the cost base is far higher than for a synthesised small molecule.
Sources et lectures complémentaires
Chaque fait ci-dessus est traçable vers une source primaire publique. Nous citons les régulateurs et les organismes de santé publique, pas les vendeurs commerciaux.
- 1Biosimilar Medicines OverviewEuropean Medicines Agency
- 2Generic Drug FactsU.S. Food & Drug Administration
- 3MedlinePlus Drug InformationU.S. National Library of Medicine
- 4WHO Prequalification of Medical ProductsWorld Health Organization
Comment cet article a été rédigé
Rédigé et recherché
Health Economics Editor, Jivan Editorial TeamRelu éditorialement
Editorial Review Board — Jivan
Regulatory mechanisms verified against primary sources.
Avertissement médical important
Consultez toujours un médecin avant de changer de médicament, de dose ou de marque. Jivan fournit des informations éducatives et tarifaires et ne remplace ni un diagnostic ni les soins d'urgence.